These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 29947012)

  • 61. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature.
    Watanabe T; Firat E; Scholber J; Gaedicke S; Heinrich C; Luo R; Ehrat N; Multhoff G; Schmitt-Graeff A; Grosu AL; Abdollahi A; Hassel JC; von Bubnoff D; Meiss F; Niedermann G
    Cancer Immunol Immunother; 2020 Sep; 69(9):1823-1832. PubMed ID: 32350591
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PD-1 blockade for disseminated Kaposi sarcoma in a patient with atopic dermatitis and chronic CD8 lymphopenia.
    Gambichler T; Susok L
    Immunotherapy; 2020 May; 12(7):451-457. PubMed ID: 32316815
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy.
    Wang M; Yao LC; Cheng M; Cai D; Martinek J; Pan CX; Shi W; Ma AH; De Vere White RW; Airhart S; Liu ET; Banchereau J; Brehm MA; Greiner DL; Shultz LD; Palucka K; Keck JG
    FASEB J; 2018 Mar; 32(3):1537-1549. PubMed ID: 29146734
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cholesterol Induces CD8
    Ma X; Bi E; Lu Y; Su P; Huang C; Liu L; Wang Q; Yang M; Kalady MF; Qian J; Zhang A; Gupte AA; Hamilton DJ; Zheng C; Yi Q
    Cell Metab; 2019 Jul; 30(1):143-156.e5. PubMed ID: 31031094
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cancer immunosurveillance by CD8 T cells.
    Crispin JC; Tsokos GC
    F1000Res; 2020; 9():. PubMed ID: 32089832
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy.
    He QF; Xu Y; Li J; Huang ZM; Li XH; Wang X
    Brief Funct Genomics; 2019 Mar; 18(2):99-106. PubMed ID: 29554204
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles.
    Graves M; CelliMarchett G; van Zyl B; Tang D; Vilain RE; van der Westhuizen A; Bowden NA
    Front Med (Lausanne); 2019; 6():113. PubMed ID: 31192212
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value.
    Music M; Iafolla MAJ; Ren AH; Soosaipillai A; Prassas I; Diamandis EP
    Mol Cancer Ther; 2019 Oct; 18(10):1844-1851. PubMed ID: 31363009
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy.
    Hashimoto M; Ramalingam SS; Ahmed R
    Trends Cancer; 2024 Apr; 10(4):332-346. PubMed ID: 38129234
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PD-L1 expression in keratinocyte and infiltration of CD4 + T lymphocyte can predict a severe type of erythema multiforme major induced by the anti-PD-1 antibody, pembrolizumab.
    Kadoi R; Yoshida T; Noto M; Toyoshima A; Fujii S; Fukuda K; Shimazu K; Taguchi D; Shinozaki H; Kodama N; Kono M; Nanjyo H; Shibata H
    Int Cancer Conf J; 2024 Jul; 13(3):268-274. PubMed ID: 38962048
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pembrolizumab-Induced Acute Skin Reaction: A Case Report and Review of Literature.
    Thomas M; Wazir A; Poudel A
    Cureus; 2022 Jun; 14(6):e26143. PubMed ID: 35754442
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer.
    Poma AM; Bruno R; Pietrini I; Alì G; Pasquini G; Proietti A; Vasile E; Cappelli S; Chella A; Fontanini G
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359727
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid.
    Portnow J; Wang D; Blanchard MS; Tran V; Alizadeh D; Starr R; Dodia R; Chiu V; Brito A; Kilpatrick J; McNamara P; Forman SJ; Badie B; Synold TW; Brown CE
    JAMA Oncol; 2020 Dec; 6(12):1947-1951. PubMed ID: 33030521
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    Yang R; Pei T; Huang R; Xiao Y; Yan J; Zhu J; Zheng C; Xiao W; Huang C
    Front Pharmacol; 2022; 13():774440. PubMed ID: 35496272
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Enhancement of Antiviral CD8
    Blanch-Lombarte O; Gálvez C; Revollo B; Jiménez-Moyano E; Llibre JM; Manzano JL; Boada A; Dalmau J; E Speiser D; Clotet B; Prado JG; Martinez-Picado J
    J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31805700
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma.
    Yamashita A; Akasaka E; Nakano H; Sawamura D
    Case Rep Dermatol; 2021; 13(3):487-491. PubMed ID: 34720923
    [TBL] [Abstract][Full Text] [Related]  

  • 77. High T-cell infiltration in tumor tissue and younger age predict the response to pembrolizumab in recurrent urothelial cancer.
    Anami T; Komohara Y; Miura Y; Yamanaka K; Kurahashi R; Segawa T; Motoshima T; Murakami Y; Yatsuda J; Yamaguchi T; Sugiyama Y; Jinnouchi Y; Kamba T
    Med Mol Morphol; 2021 Dec; 54(4):316-323. PubMed ID: 34136945
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non-small cell lung cancer after a single 200 mg administration.
    de Vries F; Smit AAJ; Wolbink G; de Vries A; Loeff FC; Franssen EJF
    Front Oncol; 2022; 12():960116. PubMed ID: 36713570
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model.
    Qiao T; Xiong Y; Feng Y; Guo W; Zhou Y; Zhao J; Jiang T; Shi C; Han Y
    Front Oncol; 2021; 11():632364. PubMed ID: 33859941
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.
    Kuryk L; Møller AW; Jaderberg M
    Oncoimmunology; 2019; 8(2):e1532763. PubMed ID: 30713786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.